Skip to content
Call Us Today! 1 (772) 595-9830 info@midwayresearch.com
FacebookTwitterLinkedInInstagram
Midway Research Center Logo Midway Research Center Logo Midway Research Center Logo
  • Home
  • About
  • Clinical Trials
    • Currently Enrolling Studies
    • Active, not recruiting Studies
    • What is a Clinical Trial?
    • Expectations
    • Studies Phases
    • Informed Consent
    • Closed Studies
  • Services
    • HIV
    • STD
    • HPV
    • Lipodystrophy
  • Journal Publications
  • Contact
  • Home
  • About
  • Clinical Trials
    • Currently Enrolling Studies
    • Active, not recruiting Studies
    • What is a Clinical Trial?
    • Expectations
    • Studies Phases
    • Informed Consent
    • Closed Studies
  • Services
    • HIV
    • STD
    • HPV
    • Lipodystrophy
  • Journal Publications
  • Contact

Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex With Men and Are At Risk of HIV-1 Infection (DISCOVER)

Home/Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex With Men and Are At Risk of HIV-1 Infection (DISCOVER)
Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex With Men and Are At Risk of HIV-1 Infection (DISCOVER)midwayadmin2019-10-28T19:17:35+00:00

Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex With Men and Are At Risk of HIV-1 Infection (DISCOVER)

GS-US-412-2055 · Trial ·

Read more

© Copyright 2012 -    |   AVADA THEME BY THEMEFUSION   |   ALL RIGHTS RESERVED   |   POWERED BY WORDPRESS
FacebookTwitterLinkedInInstagram